Seres Therapeutics (NASDAQ:MCRB – Get Rating) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Sunday.
Several other research analysts have also recently issued reports on the company. Piper Sandler increased their price objective on Seres Therapeutics from $7.00 to $9.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 7th. Chardan Capital cut their price objective on Seres Therapeutics from $16.00 to $12.00 in a research report on Thursday, August 4th.
Get
Seres Therapeutics alerts:
Seres Therapeutics Price Performance
Seres Therapeutics stock opened at $8.14 on Friday. Seres Therapeutics has a 12 month low of $2.50 and a 12 month high of $11.69. The company has a debt-to-equity ratio of 2.20, a current ratio of 2.35 and a quick ratio of 2.35. The business has a 50 day simple moving average of $6.61 and a 200-day simple moving average of $4.94. The stock has a market capitalization of $1.01 billion, a PE ratio of -3.46 and a beta of 2.81.
Seres Therapeutics (NASDAQ:MCRB – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). Seres Therapeutics had a negative return on equity of 294.70% and a negative net
margin of 1,729.94%. The company had revenue of $3.44 million for the quarter, compared to analysts' expectations of $12.29 million. Equities analysts predict that Seres Therapeutics will post -2.12 earnings per share for the current year.
Insiders Place Their Bets
In other Seres Therapeutics news, insider David S. Ege sold 5,012 shares of the stock in a transaction on Monday, October 31st. The stock was sold at an average price of $7.93, for a total value of $39,745.16. Following the completion of the transaction, the insider now owns 46,734 shares in the company, valued at $370,600.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.20% of the stock is currently owned by company insiders.
Institutional Trading of Seres Therapeutics
Several large investors have recently bought and sold shares of the company. Janney Montgomery Scott LLC grew its holdings in Seres Therapeutics by 2.4% in the third quarter. Janney Montgomery Scott LLC now owns 84,800 shares of the biotechnology company's stock valued at $544,000 after purchasing an additional 2,000 shares during the last quarter. Credit Suisse AG grew its holdings in Seres Therapeutics by 4.1% in the second quarter. Credit Suisse AG now owns 90,359 shares of the biotechnology company's stock valued at $309,000 after purchasing an additional 3,532 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Seres Therapeutics by 54.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,668 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 3,775 shares during the last quarter. Strs Ohio grew its holdings in Seres Therapeutics by 4.2% in the first quarter. Strs Ohio now owns 102,800 shares of the biotechnology company's stock valued at $731,000 after purchasing an additional 4,100 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in shares of Seres Therapeutics by 38.4% during the first quarter. E Fund Management Co. Ltd. now owns 14,871 shares of the biotechnology company's stock valued at $106,000 after acquiring an additional 4,127 shares during the last quarter. Institutional investors and hedge funds own 96.09% of the company's stock.
About Seres Therapeutics
(Get Rating)
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
See Also
- Get a free copy of the StockNews.com research report on Seres Therapeutics (MCRB)
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn't Belong In The Doghouse
- Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
- Mixed Results Actually Bring More Optimism than Risk for AMD
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
